Description
VE-821 is an inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, a chromatin-remodeling protein that senses DNA damage and activates the DNA damage checkpoint to induce cell cycle arrest. VE-821 exhibits anticancer activity, inducing chromosome fragmentation, apoptosis, and cell death in vitro. VE-821 decreases phosphorylation of Chk1 and induces G2 phase cell cycle arrest in pancreatic cancer cells and leukemia cells, sensitizing them to the effects of radiation.
References
Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16;347(6219):273-7. PMID: 25593184.
Vávrová J, Zárybnická L, Lukášová E, et al. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat Environ Biophys. 2013 Nov;52(4):471-9. PMID: 23934411.
Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012 Sep;13(11):1072-81. PMID: 22825331.
Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011 Apr 13;7(7):428-30. PMID: 21490603.